Chembio takes rapid HIV tests to the US
This article was originally published in Clinica
Paving its entry into the lucrative US HIV testing market, Chembio Diagnostics has gained FDA approval for its rapid HIV tests. Clearance of its Sure Check HIV 1/2 and HIV 1/2 Stat-Pak tests will allow the company to tap into a US rapid HIV test professional market that it believes will exceed $50m within the next couple of years. Chembio is currently in discussions with a partner to market the products in the US.